Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, prospective, open label, comparative, parallel group, multicentre 12 weeks study to evaluate efficacy, safety and tolerability of Glycopyrronium/Formoterol FDC 25mcg/12mcg twice daily in comparison with Glycopyrronium 50mcg once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A randomized, prospective, open label, comparative, parallel group, multicentre 12 weeks study to evaluate efficacy, safety and tolerability of Glycopyrronium/Formoterol FDC 25mcg/12mcg twice daily in comparison with Glycopyrronium 50mcg once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Formoterol/glycopyrrolate (Primary) ; Glycopyrrolate
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Cipla
  • Most Recent Events

    • 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top